- Home
- HGV vs MLYS Comparison
HGV vs MLYS Comparison
Compare HGV & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGV
- MLYS
- Stock Information
- Founded
- HGV 1992
- MLYS 2019
- Country
- HGV United States
- MLYS United States
- Employees
- HGV N/A
- MLYS N/A
- Industry
- HGV Hotels/Resorts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- HGV Consumer Discretionary
- MLYS Health Care
- Exchange
- HGV Nasdaq
- MLYS Nasdaq
- Market Cap
- HGV 3.7B
- MLYS 3.1B
- IPO Year
- HGV N/A
- MLYS 2023
- Fundamental
- Price
- HGV $44.16
- MLYS $40.14
- Analyst Decision
- HGV Buy
- MLYS Strong Buy
- Analyst Count
- HGV 7
- MLYS 6
- Target Price
- HGV $51.29
- MLYS $42.60
- AVG Volume (30 Days)
- HGV 772.5K
- MLYS 1.1M
- Earning Date
- HGV 10-30-2025
- MLYS 11-12-2025
- Dividend Yield
- HGV N/A
- MLYS N/A
- EPS Growth
- HGV N/A
- MLYS N/A
- EPS
- HGV 0.57
- MLYS N/A
- Revenue
- HGV $4,478,000,000.00
- MLYS N/A
- Revenue This Year
- HGV $16.51
- MLYS N/A
- Revenue Next Year
- HGV $7.67
- MLYS N/A
- P/E Ratio
- HGV $77.40
- MLYS N/A
- Revenue Growth
- HGV 12.43
- MLYS N/A
- 52 Week Low
- HGV $30.59
- MLYS $8.24
- 52 Week High
- HGV $52.08
- MLYS $44.80
- Technical
- Relative Strength Index (RSI)
- HGV 50.48
- MLYS 56.57
- Support Level
- HGV $43.74
- MLYS $39.80
- Resistance Level
- HGV $46.21
- MLYS $41.60
- Average True Range (ATR)
- HGV 1.33
- MLYS 2.02
- MACD
- HGV 0.23
- MLYS -0.87
- Stochastic Oscillator
- HGV 61.05
- MLYS 23.64
About HGV Hilton Grand Vacations Inc.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.